Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor, was…Opicapone in Parkinson’s disease – a centre’s real-life experience
Objective: To evaluate the therapeutic benefits, safety and tolerability of opicapone in a centre’s clinical practice. Background: Opicapone is a recent treatment for motor fluctuations…Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with duration of motor fluctuations of…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact of opicapone (OPC) on PDQ-39 in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a once-daily COMT…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »